Advertisement

Surgical Endoscopy

, Volume 29, Issue 11, pp 3298–3303 | Cite as

One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity

  • Bryan J. Sandler
  • Roberto Rumbaut
  • C. Paul Swain
  • Gustavo Torres
  • Luis Morales
  • Lizcelly Gonzales
  • Sarah Schultz
  • Mark  A. Talamini
  • Garth R. Jacobsen
  • Santiago Horgan
Article

Abstract

Introduction

Here, we report the first series of patients with 1-year implantation of a novel, endoluminal, endoscopically delivered and retrieved gastro-duodeno-jejunal bypass sleeve (GJBS) (ValenTx, Inc. Carpinteria, CA, USA). In this report, we present the safety, feasibility of the device, weight loss, and changes in comorbidities.

Methods and procedures

A prospective, single-center, 12-month trial was designed. The patients are morbidly obese individuals who meet the NIH criteria for bariatric surgery. The GJBS is a 120-cm sleeve secured at the esophago-gastric junction with endoscopic and laparoscopic techniques that is designed to create an endoluminal gastro-duodeno-jejunal bypass. The device was implanted and, at the completion of the trial, retrieved with an endoscopic technique. The primary endpoints were safety and incidence of adverse events. The secondary outcomes included the percentage of excess weight loss (EWL) and changes in comorbidities, specifically glucose control, use of antihyperglycemics, and changes in hemoglobin A1C levels.

Results

From July 2009 until October 2009, 13 patients were prospectively enrolled for the 1-year trial. The study included five men and eight women with a mean preoperative BMI of 42 kg/m2. One patient was excluded, at the time of endoscopic evaluation, due to inflammation at the GE junction. Two additional patients required early explantation of the device, within the first 4 weeks, due to patient intolerance. Upon explant of the device, both patients’ symptoms improved. In the remaining ten patients, the device was implanted, left in situ for 12 months, and then retrieved endoscopically. Safe delivery of the cuff at the gastro-esophageal junction was seen in all ten patients whom had device implants, without complication. No esophageal leak was seen immediately post-procedure or during follow-up. The sleeve device was well tolerated within the bowel lumen during the 12-month study, specifically, no bowel erosions, ulceration, or pancreatitis was observed. All ten patients reached the 1-year mark. Of the ten, six had fully attached and functional devices throughout the follow-up, verified by endoscopy. The mean percentage EWL, at 1 year, in this group was 54 %. In the remaining four patients, partial cuff detachment was observed at follow-up endoscopy. The percentage EWL was lower in this group. Of the six patients that reached a year with a fully attached device, five were followed at an average of 14-months post-explant (26 months from the time of device implant). These five maintained an average percentage EWL of 30 % at the 14-month post-explant follow-up. Co-morbidites measured included diabetes mellitus, hypertension, hyperlipidemia, and use of antihyperglycemics. Each of the measured comorbidities showed improvement during the 12-month trial.

Discussion

The endoluminal, GJBS can be safely placed and retrieved. The short-term data show it is well tolerated with a good safety profile. It achieves excellent weight loss results with over 70 % of all comorbidities resolved or significantly improved.

Keywords

Bariatric Clinical papers/trials/research G-I < endoscopy Endocrinology Surgical < technical 

Notes

Disclosures

Bryan J. Sandler, Roberto Rumbaut, Gustavo Torres, Luis Morales, and Lizcelly Gonzales have served as consultants for ValenTx Corporation. Santiago Horgan and C. Paul Swain have served as consultants for and have an equity interest in ValenTx Corporation. Sarah Schultz, Mark A. Talamini, and Garth Jacobsen have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Freedman DS (2011) Obesity—United States, 1988–2008. MMWR Surveill Summ 60(Suppl):73–77PubMedGoogle Scholar
  2. 2.
    Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378(9793):815–825CrossRefPubMedGoogle Scholar
  3. 3.
    Padwal R, Li SK, Lau DC (2004) Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 3:004094Google Scholar
  4. 4.
    Livingston EH (2005) Complications of bariatric surgery. Surg Clin North Am 85(4):853–868CrossRefPubMedGoogle Scholar
  5. 5.
    Ryou M, Ryan MB, Thompson CC (2011) Current status of endoluminal bariatric procedures for primary and revision indications. Gastrointest Endosc Clin N Am 21(2):315–333PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Brethauer SA, Chand B, Schauer PR, Thompson CC (2010) Transoral gastric volume reduction for weight management: technique and feasibility in 18 patients. Surg Obes Relat Dis 6(6):689–694CrossRefPubMedGoogle Scholar
  7. 7.
    Horgan S, Jacobsen G, Weiss GD, Oldham JS Jr, Denk PM, Borao F, Gorcey S, Watkins B, Mobley J, Thompson K, Spivack A, Voellinger D, Thompson C, Swanstrom L, Shah P, Haber G, Brengman M, Schroder G (2010) Incisionless revision of post-Roux-en-Y bypass stomal and pouch dilation: multicenter registry results. Surg Obes Relat Dis 6(3):290–295CrossRefPubMedGoogle Scholar
  8. 8.
    Schurr MO, Ho CN, Rieber F, Fleisch C, Coscarella G, Tognoni V, Di Lorenzo N (2009) Implantable endoscopic gastric bypass—device and experimental procedure. Minim Invasive Ther Allied Technol 18(5):273–279CrossRefPubMedGoogle Scholar
  9. 9.
    Tarnoff M, Shikora S, Lembo A (2008) Acute technical feasibility of an endoscopic duodenal-jejunal bypass sleeve in a porcine model: a potentially novel treatment for obesity and type 2 diabetes. Surg Endosc 22(3):772–776CrossRefPubMedGoogle Scholar
  10. 10.
    Sandler BJ, Rumbaut R, Paul Swain C, Torres G, Morales L, Gonzales L, Schultz S, Talamini M, Horgan S (2011) Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 25(9):3028–3033CrossRefPubMedGoogle Scholar
  11. 11.
    Gadde KM, Allison DB (2009) Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes 16(5):353–358CrossRefPubMedGoogle Scholar
  12. 12.
    Bondada S, Jen HC, Deugart DA (2011) Outcomes of bariatric surgery in adolescents. Curr Opin Pediatr 23(5):552–556CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bryan J. Sandler
    • 1
  • Roberto Rumbaut
    • 2
  • C. Paul Swain
    • 3
  • Gustavo Torres
    • 2
  • Luis Morales
    • 2
  • Lizcelly Gonzales
    • 2
  • Sarah Schultz
    • 1
  • Mark  A. Talamini
    • 4
  • Garth R. Jacobsen
    • 1
  • Santiago Horgan
    • 1
  1. 1.Division of Minimally Invasive Surgery, Department of SurgeryUC San DiegoSan DiegoUSA
  2. 2.Hospital de Tec de MonterreyMonterreyMexico
  3. 3.Imperial College of LondonLondonUK
  4. 4.Department of SurgeryStony Brook MedicineStony BrookUSA

Personalised recommendations